Korro Bio (KRRO) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $9.31, +4.84% vs the prior close of $8.88.
- Volume 440.10K shares, 3.0x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
KRRO jumps 4.8% to $9.31 on 3.0x normal volume. Closed at $9.31, +4.84% vs the prior close of $8.88. Day range $8.53–$9.78, opened at $8.93.
KRRO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — KRRO jumps 4.8% to $9.31 on 3.0x normal volume
- Closed at $9.31, +4.84% vs the prior close of $8.88. Day range $8.53–$9.78, opened at $8.93.
- Volume was 440.10K shares, 3.0x its 50-day average of 147.58K — unusually heavy trading.
- Price is -20.8% vs its 50-day average ($11.75) and -20.9% vs its 200-day average ($11.76).
- 52-week range $5.20–$55.89; today's close sits at 8% of that range, 83.3% below the 52-week high.
Oct 14, 2026 — KRRO rises 0.8% to $8.88
- Closed at $8.88, +0.79% vs the prior close of $8.81. Day range $8.34–$9.13, opened at $8.62.
- Volume was 216.40K shares, 1.5x its 50-day average of 145.90K.
- Price is -24.7% vs its 50-day average ($11.80) and -24.5% vs its 200-day average ($11.76).
- 52-week range $5.20–$55.89; today's close sits at 7% of that range, 84.1% below the 52-week high.
Oct 13, 2026 — KRRO slides 6.0% to $8.81, a 6-month low on 1.9x normal volume
- Closed at $8.81, -5.98% vs the prior close of $9.37. Day range $8.55–$9.39, opened at $9.37.
- Volume was 263.70K shares, 1.9x its 50-day average of 142.52K — unusually heavy trading.
- Price is -25.6% vs its 50-day average ($11.85) and -25.0% vs its 200-day average ($11.75).
- 52-week range $5.20–$55.89; today's close sits at 7% of that range, 84.2% below the 52-week high.
- That makes 3 straight losses.
Oct 12, 2026 — KRRO slides 7.8% to $9.37, a 3-month low
- Closed at $9.37, -7.78% vs the prior close of $10.16. Day range $9.32–$10.26, opened at $10.09.
- Volume was 140.40K shares, 1.0x its 50-day average of 142.01K.
- Price is -21.2% vs its 50-day average ($11.88) and -20.3% vs its 200-day average ($11.75).
- 52-week range $5.20–$55.89; today's close sits at 8% of that range, 83.2% below the 52-week high.
Oct 9, 2026 — KRRO slides 4.0% to $10.16
- Closed at $10.16, -3.97% vs the prior close of $10.58. Day range $10.12–$10.78, opened at $10.60.
- Volume was 133.50K shares, 0.9x its 50-day average of 141.94K.
- Price is -14.7% vs its 50-day average ($11.90) and -13.5% vs its 200-day average ($11.75).
- 52-week range $5.20–$55.89; today's close sits at 10% of that range, 81.8% below the 52-week high.
Oct 8, 2026 — KRRO rises 0.9% to $10.58
- Closed at $10.58, +0.86% vs the prior close of $10.49. Day range $10.18–$10.64, opened at $10.36.
- Volume was 167.20K shares, 1.2x its 50-day average of 141.24K.
- Price is -11.2% vs its 50-day average ($11.91) and -9.8% vs its 200-day average ($11.74).
- 52-week range $5.20–$55.89; today's close sits at 11% of that range, 81.1% below the 52-week high.
Oct 7, 2026 — KRRO jumps 7.5% to $10.49
- Closed at $10.49, +7.48% vs the prior close of $9.76. Day range $9.50–$10.64, opened at $9.64.
- Volume was 157.00K shares, 1.1x its 50-day average of 141.18K.
- Price is -11.8% vs its 50-day average ($11.90) and -10.5% vs its 200-day average ($11.72).
- 52-week range $5.20–$55.89; today's close sits at 10% of that range, 81.2% below the 52-week high.
Oct 6, 2026 — KRRO dips 2.1% to $9.76
- Closed at $9.76, -2.11% vs the prior close of $9.97. Day range $9.47–$10.35, opened at $10.20.
- Volume was 142.60K shares, 1.0x its 50-day average of 140.95K.
- Price is -18.0% vs its 50-day average ($11.90) and -16.6% vs its 200-day average ($11.71).
- 52-week range $5.20–$55.89; today's close sits at 9% of that range, 82.5% below the 52-week high.
Oct 5, 2026 — KRRO jumps 3.4% to $9.97
- Closed at $9.97, +3.42% vs the prior close of $9.64. Day range $9.41–$10.10, opened at $9.70.
- Volume was 112.20K shares, 0.8x its 50-day average of 141.65K.
- Price is -16.4% vs its 50-day average ($11.92) and -14.8% vs its 200-day average ($11.70).
- 52-week range $5.20–$55.89; today's close sits at 9% of that range, 82.2% below the 52-week high.
- SEC filings that day: 8-K.
Oct 2, 2026 — KRRO dips 0.7% to $9.64
- Closed at $9.64, -0.72% vs the prior close of $9.71. Day range $9.48–$9.90, opened at $9.90.
- Volume was 153.10K shares, 1.1x its 50-day average of 141.35K.
- Price is -19.2% vs its 50-day average ($11.93) and -17.5% vs its 200-day average ($11.69).
- 52-week range $5.20–$55.89; today's close sits at 9% of that range, 82.8% below the 52-week high.
KRRO latest news & SEC filings
Every SEC filing by or about KRRO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 5, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Formela Jean Francois sold 31,888 shares at $14.12 (≈$450.26K) on Sep 14, 2026
- Formela Jean Francois sold 6,602 shares at $14.12 (≈$93.22K) on Sep 14, 2026
- Formela Jean Francois sold 1,750 shares at $13.99 (≈$24.48K) on Sep 11, 2026
- Formela Jean Francois sold 8,450 shares at $13.99 (≈$118.22K) on Sep 11, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 14, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Dolan Oliver sold 5 shares at $13.72 (≈$69) on Sep 11, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 11, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 19, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $1.46M) (-100.0% vs Jun 30, 2025)
- Net income: -$18.92M (prior year -$25.77M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$1.07 (prior year -$2.74) (loss narrowed vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.02 — Reported results of operations (earnings release).
- Item 3.02 — Sold unregistered shares.
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 4, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 29, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade KRRO
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 7, 2026, Mar 12, 2026, Mar 9, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.57% (largest 15.1%). That is a volatile stock.
- Liquidity: about 207.60K shares (≈$1.93M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $9.31 vs a range of $5.20–$55.89 (8% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 21 sales; latest: Jean Francois Formela sold 31,888 shares on Sep 14, 2026.
- Latest filings: 8-K Oct 5, 2026; 8-K Aug 19, 2026; 10-Q Aug 6, 2026.
- Share count: 14.73M shares outstanding (Aug 5, 2026), +56.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
KRRO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 8.93 | 9.78 | 8.53 | 9.31 | 440.10K |
| Oct 14, 2026 | 8.62 | 9.13 | 8.34 | 8.88 | 216.40K |
| Oct 13, 2026 | 9.37 | 9.39 | 8.55 | 8.81 | 263.70K |
| Oct 12, 2026 | 10.09 | 10.26 | 9.32 | 9.37 | 140.40K |
| Oct 9, 2026 | 10.60 | 10.78 | 10.12 | 10.16 | 133.50K |
| Oct 8, 2026 | 10.36 | 10.64 | 10.18 | 10.58 | 167.20K |
| Oct 7, 2026 | 9.64 | 10.64 | 9.50 | 10.49 | 157.00K |
| Oct 6, 2026 | 10.20 | 10.35 | 9.47 | 9.76 | 142.60K |
| Oct 5, 2026 | 9.70 | 10.10 | 9.41 | 9.97 | 112.20K |
| Oct 2, 2026 | 9.90 | 9.90 | 9.48 | 9.64 | 153.10K |
| Oct 1, 2026 | 9.93 | 10.27 | 9.47 | 9.71 | 88.80K |
| Sep 30, 2026 | 9.89 | 10.01 | 9.50 | 9.91 | 108.10K |
| Sep 29, 2026 | 9.56 | 9.80 | 9.30 | 9.56 | 92.90K |
| Sep 28, 2026 | 9.49 | 9.65 | 9.24 | 9.51 | 132.40K |
| Sep 25, 2026 | 9.64 | 9.64 | 9.40 | 9.57 | 114.40K |
| Sep 24, 2026 | 9.71 | 9.75 | 9.41 | 9.57 | 197.50K |
| Sep 23, 2026 | 10.31 | 10.31 | 9.55 | 9.83 | 224.70K |
| Sep 22, 2026 | 10.08 | 10.58 | 10.01 | 10.34 | 213.50K |
| Sep 21, 2026 | 10.12 | 10.77 | 9.86 | 9.98 | 290.40K |
| Sep 18, 2026 | 11.71 | 11.94 | 9.51 | 10.02 | 763.10K |
About Korro Bio
Korro Bio (KRRO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in CAMBRIDGE, MA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1703647.
KRRO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Ram Aiyar | President and CEO | Aug 5, 2026 |
| Ali Behbahani | Director | Jun 11, 2026 |
| Nessan Bermingham | Director | Jun 11, 2026 |
| Jean Francois Formela | Director | Sep 15, 2026 |
| Katharine Knobil | Director | Jun 11, 2026 |
| Rachel Meyers | Director | Jun 11, 2026 |
| Timothy R Pearson | Director | Jun 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Ram Aiyar | President and CEO | Aug 5, 2026 |
| Jeffrey Cerio | General Counsel | Jul 17, 2026 |
| Todd Chappell | Chief Operating Officer | Jul 17, 2026 |
| Oliver Dolan | Senior Vice President, Finance | Sep 14, 2026 |
| Loic A Vincent | Chief Scientific Officer | Jul 17, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 14, 2026 | Jean Francois Formela | Sale | 31,888 | $14.12 |
| Sep 14, 2026 | Jean Francois Formela | Sale | 6,602 | $14.12 |
| Sep 11, 2026 | Jean Francois Formela | Sale | 1,750 | $13.99 |
| Sep 11, 2026 | Jean Francois Formela | Sale | 8,450 | $13.99 |
| Sep 11, 2026 | Oliver Dolan | Sale | 5 | $13.72 |
| Sep 9, 2026 | Oliver Dolan | Sale | 6 | $13.60 |
| Sep 8, 2026 | Oliver Dolan | Sale | 7,347 | $13.51 |
| Aug 26, 2026 | Jean Francois Formela | Sale | 249 | $13.96 |
| Aug 26, 2026 | Jean Francois Formela | Sale | 51 | $13.96 |
| Aug 19, 2026 | Jean Francois Formela | Sale | 23,584 | $14.00 |
| Aug 19, 2026 | Jean Francois Formela | Sale | 4,884 | $14.00 |
| Aug 11, 2026 | Jean Francois Formela | Sale | 1,775 | $13.96 |
| Aug 11, 2026 | Jean Francois Formela | Sale | 368 | $13.96 |
| Aug 10, 2026 | Capital Management Lp Lynx1 | Buy | 1,462 | $13.19 |
| Aug 10, 2026 | Weston Nichols | Buy | 1,462 | $13.19 |
KRRO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-117.26M | -12.48 | $-78.56M |
| Dec 31, 2024 | — | $-83.58M | -9.37 | $-60.07M |
| Dec 31, 2023 | — | $-81.17M | -53.08 | $-67.28M |
| Dec 31, 2022 | $0 | $-58.03M | -227.42 | $-53.65M |
| Dec 31, 2021 | $14.07M | $-84.69M | — | $-76.06M |
Latest balance sheet: total assets $163.45M, total liabilities $60.22M, cash $24.91M (as of Jun 30, 2026).
KRRO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $12.12 |
| May 7, 2026 | 8-K Item 2.02 (results) | $12.89 |
| Mar 12, 2026 | 8-K Item 2.02 (results) | $11.50 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $12.30 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $31.42 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $15.99 |
| May 7, 2025 | 8-K Item 2.02 (results) | $13.93 |
| Mar 18, 2025 | 8-K Item 2.02 (results) | $24.17 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $65.14 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 26, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Regeneron Pharmaceuticals (REGN)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on KRRO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.